Pritchard Capital Partners increases its price from $140 to $160 on Buy-rated Core Laboratories CLB following a strong quarter report.
Pritchard Capital Partners notes, "We are even more optimistic following the CLB call. We are tweaking our Q2 EPS estimate to account for a potential increase in expenses related to the new listing. Keeping our 2012 and 2013 EPS estimates and increasing our target price to $160 up from $140. CLB continues to be one of our top picks."
CLB closed at $130.48 on Wednesday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Posted In: Analyst ColorPrice TargetReiterationPre-Market OutlookAnalyst RatingsPritchard Capital Partners
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in